CAPCOM
29.8.2024 14:01:29 CEST | Business Wire | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that the company will sponsor the Osaka Healthcare Pavilion, which is being exhibited by the Expo 2025, Osaka Pavilion Promotion Committee at Expo 2025, Osaka, Kansai, Japan (Expo 2025, below). Further, the company announced that it will exhibit an interactive experience dubbed Monster Hunter Bridge at the Pavilion in the XD Hall, where visitors can experience the future of entertainment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829488620/en/
Monster Hunter Bridge key art (Graphic: Business Wire)
The theme of the upcoming Expo 2025 is “Designing Future Society for Our Lives.” Inspired by the “REBORN” theme of the Osaka Healthcare Pavilion, Capcom decided to exhibit an interactive attraction that incorporates the concept of nature, living things, and the wonder of life, which are important themes in the Monster Hunter series.
Exhibit Details
Monster Hunter Bridge is a wholly-unique attraction that Capcom created exclusively for Expo 2025. Visitors to the hall will don specialized AR devices and be able to enjoy this interactive attraction that weaves together a 360-degree theater, immersive audio, and vibrating floor. Capcom is developing Monster Hunter Bridge with the aim of blending dreams with reality to provide an immersive experience like never before. The company hopes that visitors look forward to this one-of-a-kind Monster Hunter attraction that will bring them up close with Felyne as well as incredible monster encounters, and can only be experienced at Expo 2025.
Facilities Details
The attraction will be housed in a cylinder-shaped theater within the XD Hall that will measure approximately 12 meters in diameter and 5 meters in height and will be created as part of the Osaka Healthcare Pavilion. Capcom will exhibit Monster Hunter Bridge there by creating a space inside the XD Hall that projects the world of Monster Hunter in 360 degrees, utilizing transparent LED displays on the internal walls and ceiling and projectors on the floor. The company developed new specialized AR devices for visitors that feature 105 degrees of visibility in order to create Expo 2025’s most engaging experience. In addition, the company will enhance the immersion of the space by outfitting it with a multitude of speakers set behind the transparent LED displays, wrapping visitors in 360 degrees of sound while vibrations from the floor are synchronized with the on-screen action.
The company is creating these facilities with the cooperation of partner companies exclusively for Monster Hunter Bridge.
Promotional Ticket Campaign
With the desire to contribute to the development and promotion of Expo 2025, which is being held where Capcom was founded, the company will carry out an Expo 2025 “super-advanced one-day pass” double ticket promotional campaign in which it will give away a total of 80,890 tickets to Expo 2025. The promotion is available to everyone who registers for Capcom ID, a unified account with which users can conveniently manage various Capcom games and web services. The company encourages people to refer to the promotional ticket campaign website for more details.
*Only residents of Japan are eligible to participate in the round one entry period. Please refer to the promotional ticket campaign website regarding eligibility for future campaign entry periods.
Capcom is currently developing Monster Hunter Bridge with the aim of providing a special entertainment experience where dreams and reality become one. The company hopes to create the absolute best content at the event and bring success to the Expo 2025, Osaka Pavilion Promotion Committee.
ABOUT the Monster Hunter series:
The Monster Hunter series consists of hunting action games that pit players against giant monsters in beautiful natural environments. After the series created a social phenomenon through play on handheld consoles and solidified its standing as one of Japan’s most beloved game series, it went on to global-brand status with the release of Monster Hunter: World in 2018. With cumulative sales of the series now exceeding 100 million units, Monster Hunter has grown into a global phenomenon.
[Exhibit Details]
1. Name |
Monster Hunter Bridge |
2. Location |
XD Hall, Osaka Healthcare Pavilion, Expo 2025, Osaka, Kansai |
3. Term |
April 13, 2025 - October 13, 2025 |
4. Admission |
Free* |
5. Official Website |
|
6. Ticket Promotion Website |
|
*Entry to this attraction will be by reservation only. Details will be provided at a later date. |
|
*A separate ticket must be purchased to enter Expo 2025, Osaka, Kansai. |
|
ABOUT CAPCOM
Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829488620/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom